Arcutis has achieved a pivotal profitability inflection, with Q2 2026 revenue surging 59.3% year-over-year to $129.9M and operating income turning positive at $16.4M, driven by ZORYVE's commercial traction and a 91.6% gross margin.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.06-66.7% vs $0.18 | $144M+0.9% vs $143M |
Q3 2026 Aug 5, 2026 | $0.11+99.7% vs $0.06 | $130M+9.3% vs $119M |
Q2 2026 May 6, 2026 | -$0.09-350.0% vs -$0.02 | $105M+1.7% vs $104M |
Q1 2026 Feb 25, 2026 | $0.13+333.3% vs $0.03 | $130M+14.5% vs $113M |
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) EVP Masaru Matsuda sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $34.32, for a total transaction of $1,372,800.00. Following the completion of the transaction, the executive vice president owned 111,289 shares
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 58,500 restricted stock units (RSUs) of Arcutis common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of November 2, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment to individuals with moderate to severe atopic dermatitis Builds on existing evidence of ZORYVE cream 0.15% for individuals ages 6 and older and ZORYVE cream 0.05% for children ages 2 to 5 with mild to moderate atopic dermatitis WESTLAKE VILLAGE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 3, double-blind, randomized, vehicle-controlled study, INTEGUMENT-3.
Arcutis Biotherapeutics, Inc. ( ARQT ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Brian Schoelkopf - Head of Investor Relations Todd Watanabe - President, CEO & Director Robert Lisicki - Interim Executive VP & Chief Commercial Officer Patrick Burnett - Executive VP & Chief Medical Officer Latha Vairavan - Senior VP & Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Lin Tsai - Jefferies LLC, Research Division Ikenna Okafor - TD Cowen, Research Division Parth Patel - Morgan Stanley, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division John Gionco - Needham & Company, LLC, Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.
Benchmark ARQT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Arcutis Biotherapeutics, Inc. (ARQT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.55 | $3.2B | 116.88 | 91.34% | 5.88% | 14.18% | — | |
| $4.47 | $123.02M | -20.14 | 10.2% | -8.95% | -20.23% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — |
Arcutis Biotherapeutics, Inc. (ARQT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Arcutis Biotherapeutics, Inc. (ARQT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 16, 2026·SEC
Jun 9, 2026·SEC
Get notified when ARQT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arcutis Biotherapeutics, Inc. (ARQT) stock FAQ — growth, dividends, profitability & financials explained
Arcutis Biotherapeutics, Inc. (ARQT) reported $508.7M in revenue over the trailing twelve months. Revenue was $376.1M in fiscal year 2025.
Arcutis Biotherapeutics, Inc. (ARQT) grew revenue by 60.0% over the trailing twelve months, compared with the twelve months before.
Yes. Arcutis Biotherapeutics, Inc. (ARQT) earned $29.9M in net income over the trailing twelve months (a 5.9% net margin).
Arcutis Biotherapeutics, Inc. (ARQT) had a return on equity (ROE) of 14.2% over the trailing twelve months. That is in line with the market's typical 10-15%.
Arcutis Biotherapeutics, Inc. (ARQT) generated $59.7M in free cash flow over the trailing twelve months.
